Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies

Summarizes preclinical and clinical evidence on ayahuasca—a traditional Amazonian brew combining N, N-Dimethyltryptamine (DMT) and β-carbolines—in treating depression, anxiety, post-traumatic stress disorder, substance use, eating, and personality disorders. Preclinical work shows enhanced neuroplasticity, reduced inflammation, and oxidative stress. Human neuroimaging reveals decreased default mode network activity, increased functional connectivity and brain entropy, indicating a flexible neural state and modulation of pathways related to neuroplasticity, inflammation, and stress response. While promising, the evidence is mainly observational. Users report emotional breakthroughs, increased self-awareness, and mystical experiences tied to therapeutic outcomes. Ayahuasca appears to target core psychological and neurobiological processes across disorders but requires caution in psychotic or bipolar individuals and should be administered with support. Randomized trials are needed to confirm efficacy and safety. In structured, culturally sensitive settings, ayahuasca/DMT may offer a novel treatment and, by integrating indigenous wisdom with modern science, deepen our understanding of healing and consciousness.